Text Size

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

This study has been terminated.
Sponsor:
Information provided by:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00100984
First received: January 7, 2005
Last updated: December 15, 2005
Last verified: December 2005
History of Changes
  Purpose

The main objective of this study is to compare the safety and efficacy of an enfuvirtide containing regimen to a nucleoside combination regimen. Resistance information will also be collected.


Condition Intervention Phase
HIV Infection
 Drug: FUZEON [enfuvirtide]
 Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Hoffmann-La Roche:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • CD4 cell count greater than 50 cells/mm^3
  • HIV-1 RNA viral load greater than or equal to 5000 copies/mL
  • Patients must be HIV treatment experienced
  • Patients diagnosed with HIV-1 infection

Exclusion Criteria:

  • Female patients must not be able to have children or must be under effective contraceptives
  • Female patients who are pregnant
  • Have taken enfuvirtide and/or T-1249 before
  • Have serious kidney problems
  • Alcohol and/or drug abuse
  • Have had an organ transplant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00100984

Locations
United States, Alabama
Hobson City, Alabama, United States, 36201
United States, California
Los Angeles, California, United States, 90036
Los Angeles, California, United States, 90033
United States, District of Columbia
Washington, District of Columbia, United States, 20009
Washington, District of Columbia, United States, 20007
United States, Florida
Orlando, Florida, United States, 32803
United States, Georgia
Atlanta, Georgia, United States, 30308
Macon, Georgia, United States, 31201
United States, Illinois
Chicago, Illinois, United States, 60657
Chicago, Illinois, United States, 60612
United States, Maryland
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Boston, Massachusetts, United States, 02215-3318
United States, Mississippi
Jackson, Mississippi, United States, 39216-4505
United States, Missouri
St. Louis, Missouri, United States, 63139
United States, New Jersey
Newark, New Jersey, United States, 07103
United States, New York
New York, New York, United States, 10011
New York, New York, United States, 10016
United States, North Carolina
Huntersville, North Carolina, United States, 28078
United States, Texas
Dallas, Texas, United States, 75246
Houston, Texas, United States, 77004
Sponsors and Collaborators
Hoffmann-La Roche
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00100984     History of Changes
Other Study ID Numbers: ML18021
Study First Received: January 7, 2005
Last Updated: December 15, 2005
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Enfuvirtide
 Lopinavir
HIV Fusion Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on May 19, 2013